Melanotan I is the selective, linear melanocortin receptor agonist that produces UV-protective melanin production with a cleaner side-effect profile than its cyclic counterpart Melanotan II.
Research Applications
Photoprotective melanogenesis, EPP treatment, UV damage prevention research, and MC1R receptor pharmacology.
Dosage Information (Research Use)
Research protocols: 0.5-1 mg subcutaneously daily during loading, then maintenance. UV exposure required for visible effect. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Approximately 30 minutes.
Reported Observations in Literature
Nausea (common initially), facial flushing. Significantly fewer off-target effects than Melanotan II. Mole monitoring recommended.
Key Research References
- Dorr RT, et al. “Effects of Melanotan I on melanin synthesis.” Photochem Photobiol. 2004